Retina. 2022 Aug 12. doi: 10.1097/IAE.0000000000003594. Online ahead of print.
ABSTRACT
PURPOSE: To investigate the impact of baseline vitreomacular interface (VMI) status on treatment outcomes in patients treated with three different anti-vascular endothelial growth factors (anti-VEGF) for diabetic macular edema (DME).
METHODS: Post-hoc analysis from patients enrolled in the DRCR.net Protocol T study. Optical coherence tomography images were analyzed at baseline and at the end of follow-up to identify the presence of complete vitreomacular adhesion (VMA), partial vitreomacular adhesion, vitreomacular traction syndrome and complete posterior vitreous detachment (PVD).
RESULTS: Six hundred twenty-nine eyes were eligible for the study based on the study criteria. Complete adhesion eyes gained on average +3.7 more ETDRS letters compared to the complete PVD group at the end of the 12 months follow-up (p < 0.001). Baseline VMI status had no significant influence on CST at 12 months (p=0.144). There was no difference between the treatment arms based on effect of baseline VMI status on BCVA gain.
CONCLUSIONS: This study provides evidence that VMI status affects functional outcomes in DME patients treated with anti-VEGF injections. The presence of complete or partial VMA at baseline might be associated with a larger treatment benefit than those with complete PVD.
PMID:35962998 | DOI:10.1097/IAE.0000000000003594
